AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Mizuho Securities Reiterates Neutral Rating on Amgen (AMGN), PT $208, 'Lukewarm Lumakras ESMO Data'
September 12, 2022 9:44 AM EDTMizuho Securities analyst Salim Syed reiterated a Neutral rating and $208.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "And last night, we received the first part of detailed data from Amgen's Ph3 CB200 trial (Lumakras in 2L+ NSCLC). While we expect to receive the second part of detailed data later today, the first part showed (a) a decrease in ORR from 36% in CB100 to yesterday's 28%, (b) Gr3 liver enzyme elevations in about 10% of patients -- known... More
